Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 8973 results

  1. Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

  2. Gout

    Awaiting development Reference number: GID-QS10100 Expected publication date: TBC

  3. Surgical mesh for treatment of non-primary ventral hernias

    In development Reference number: GID-HTG10165 Expected publication date: TBC

  4. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11987 Expected publication date: TBC

  5. Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]

    In development Reference number: GID-TA11959 Expected publication date: TBC

  6. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  15 July 2026

  7. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTE10090 Expected publication date:  10 March 2027

  8. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    In development Reference number: GID-TA11509 Expected publication date:  24 February 2027

  9. Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

    In development Reference number: GID-NG10444 Expected publication date:  17 June 2026

  10. Teprotumumab for treating thyroid eye disease [ID6432]

    Deferred Reference number: GID-TA11531

  11. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

  12. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  13. Pulmonary sarcoidosis: infliximab (ES2)

    Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

  14. Antimicrobial prescribing: meropenem with vaborbactam (ES21)

    Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making